에이비온

203400KOSDAQ

60.5 / 100

Reference Date: 2026-10-23

Financial Score20.0 / 40

News Sentiment12.5 / 25

Momentum18.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Surged 400.0% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

ABION is a KOSDAQ-listed biopharmaceutical company specializing in the development of anti-cancer drugs and candidates based on companion diagnostics. Key pipelines include Vabametkib for non-small cell lung cancer, ABN101 (an interferon-beta-based antiviral), and ABN501 targeting Claudin3 protein in various cancers. Approximately 95.3% of its revenue comes from government research contracts.

Number of Employees

34people

Average Salary

72.5M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 15.004.0Point

PBR

0.89Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

-60.24Industry Average 8.000.0Point

Well below industry avg

Debt Ratio

7.16Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20252.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼12.3% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲17.1% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -173.6% (improving, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position6.0Point

52w upper range (79%)

Current 3,380Won52-week high 4,10052-week low 616

1-month return6.0Point

1m +400.00% (strong rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0

Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-13
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-08
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-08